kth.sePublications KTH
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Surface-engineered bacteria in drug development
KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Protein Technology. KTH Royal Inst Technol, Dept Prot Sci, SE-10691 Stockholm, Sweden..ORCID iD: 0000-0002-9952-9814
KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Protein Technology.ORCID iD: 0000-0002-9282-0174
KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Protein Technology.ORCID iD: 0000-0001-9423-0541
2024 (English)In: Microbial Biotechnology, ISSN 1751-7907, E-ISSN 1751-7915, Microbial Biotechnology, ISSN 1751-7915, Vol. 17, no 10, article id e70033Article, review/survey (Refereed) Published
Abstract [en]

Bacterial surface display in combination with fluorescence-activated cell sorting is a versatile and robust system and an interesting alternative approach to phage display for the generation of therapeutic affinity proteins. The system enables real-time monitoring and sorting of cell populations, which presents unique possibilities for drug development. It has been used to develop several affibody molecules currently being evaluated preclinically for the treatment and diagnosis of, for example, cancer and neurodegenerative diseases. Additionally, it can be implemented in other areas of drug design, such as for mapping epitopes and evolving enzyme specificities. Bacterial surface display in combination with fluorescence-activated cell sorting is a versatile and robust system for the generation of therapeutic affinity proteins. It has been used to develop affibody molecules for the treatment and diagnosis of, for example, cancer and neurodegenerative diseases.image

Place, publisher, year, edition, pages
Wiley , 2024. Vol. 17, no 10, article id e70033
National Category
Biochemistry Molecular Biology
Identifiers
URN: urn:nbn:se:kth:diva-355306DOI: 10.1111/1751-7915.70033ISI: 001332545500001PubMedID: 39403960Scopus ID: 2-s2.0-85206274318OAI: oai:DiVA.org:kth-355306DiVA, id: diva2:1909128
Note

QC 20241030

Available from: 2024-10-30 Created: 2024-10-30 Last updated: 2025-02-20Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Leitao, Charles DahlssonStåhl, StefanLöfblom, John

Search in DiVA

By author/editor
Leitao, Charles DahlssonStåhl, StefanLöfblom, John
By organisation
Protein Technology
In the same journal
Microbial Biotechnology
BiochemistryMolecular Biology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 168 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf